The fourth arm of SOLIDARITY combines lopinavir-ritonavir with interferon-b. The
activation of innate antiviral response by interferon should have beneficial
effects at least in the initial stage of infection. However,
cautions should still be observed and the possibility that interferon
might exacerbate inflammation during the late phase of SARS-CoV-2 infection
cannot be excluded.42